Navigation Links
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Date:12/27/2007

Company Returns to Commercial Operations

SEATTLE, Dec. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq, MTAX: CTIC) today announced that it has completed its acquisition of Zevalin(R) (ibritumomab tiuxetan) from Biogen Idec, giving CTI sole responsibility for marketing, sales, and development of the drug in the United States. Zevalin will continue to be sold outside the United States by Bayer Schering under an agreement between Biogen Idec and Bayer Schering. Approved in 2002 to treat patients with relapsed indolent non-Hodgkin's lymphoma (NHL), Zevalin was the first radioimmunotherapy to be approved by the U.S. Food and Drug Administration (FDA). In 2006, Biogen Idec reported $16.4 million in U.S. Zevalin sales.

"This acquisition puts CTI back into the commercial arena, which is a relatively exclusive space for biotech companies, and also strengthens our product pipeline," said James A. Bianco, M.D., President and CEO of CTI. "Adding the commercial infrastructure now may also provide a benefit to the company for future launches of other products in our pipeline. This is especially relevant to the potential launch of pixantrone and its expected synergies with Zevalin."

CTI made an initial payment of $10 million to Biogen Idec in exchange for control of U.S. marketing, sales, and development of Zevalin. Under the terms of the acquisition agreement, CTI will pay royalties to Biogen Idec based on the net sales of Zevalin until at least December 2015, and has also agreed to pay up to an additional $20 million in milestone payments if the product receives approval from the FDA for certain first-line indications in NHL. CTI also has agreed to share the cost of certain clinical trials of Zevalin with Bayer Schering in the event such trials are undertaken. CTI was advised on the transaction by CIBC World Markets Corp.

"Zevalin is a highly effective drug now, with attractive long-term commercial potential as
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. Cell Therapeutics, Inc. Announces $6.5 Million Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... IL (PRWEB) , ... June 29, 2015 , ... ... of patented products, announces the Fresh Plus Diaper, a baby invention that makes ... diaper market is projected to reach a market value of USD 52.2 billion ...
(Date:6/29/2015)... CT (PRWEB) , ... June 29, 2015 , ... ... centers recognized by the independent auditor of customer service for the 40-center nursing ... more than 1,100 skilled nursing centers in the United States in one or ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... new approach to build nearly complete genomes by combining high-throughput DNA sequencing with ... critically important for their association with human disease, but previously difficult to detect. ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... With Urgent ... announces a partnership with the American Board of Urgent Care Medicine and the Medical ... Category 1 Credit™ to Urgent Care physicians and health care professionals. , According to ...
(Date:6/29/2015)... ... ... USA Today reported on June 18th the overdose death rate ... the rest of the nation’s growing overdose death rates in 26 other states the ... to stop the increasing overdose trend from continuing: , , Encourage ...
Breaking Medicine News(10 mins):Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3
... 4th Leading Cause of Death in U.S., SWANTON, ... Awareness Month, to help raise awareness about Chronic,Obstructive Pulmonary ... AllerAir will be making downloadable,tips available to COPD patients ... their November newsletter and blogs to raising awareness,about this ...
... TORONTO, Nov. 3 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc.,a ... cancer therapies, announced today that Dr. Alan M.,Ezrin, ... will present a,corporate update at Rodman & Renshaw ... New York City from November 10th - 12th ...
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ... Exchange ("TSX") that it is reviewing the eligibility of ... The Company is being reviewed under the TSX,s ... comply with all requirements for continued,listing. If the Company ...
... cash flow from operations, updated guidance, and new stock ... ... (Nasdaq: AMCS ), a,leader in radiology and medical image and ... ended,September 30, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ...
... out than those without deployed kin , , MONDAY, Nov. 3 ... Iraq and Afghanistan are more likely to have behavioral problems ... , Researchers studied 169 families with children aged 18 months ... at a Marine base. , Of those families, 55 (33 ...
... Cox-1 drugs, like naproxen, study says , , MONDAY, Nov. ... attack that comes with the use of nonsteroidal anti-inflammatory ... to the specific pain-causing molecule they act against, a ... between the degree of inhibition in vitro [in the ...
Cached Medicine News:Health News:AllerAir Dedicates November to COPD Awareness Month 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 3Health News:Listing Review initiated by the Toronto Stock Exchange 2Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 2Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 3Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 4Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 5Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 6Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 7Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 8Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 9Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 10Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 11Health News:AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 12Health News:Kids With Parent in War Zone Face Behavior Risks 2Health News:Study Sheds Light on Painkillers' Heart Risk 2Health News:Study Sheds Light on Painkillers' Heart Risk 3
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: